Compare RMBI & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RMBI | ADCT |
|---|---|---|
| Founded | 1887 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 143.0M | 136.1M |
| IPO Year | 2019 | 2019 |
| Metric | RMBI | ADCT |
|---|---|---|
| Price | $15.16 | $1.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 50.5K | ★ 3.4M |
| Earning Date | 04-23-2026 | 05-04-2026 |
| Dividend Yield | ★ 3.85% | N/A |
| EPS Growth | 27.17 | ★ 30.86 |
| EPS | ★ 0.28 | N/A |
| Revenue | N/A | ★ $81,357,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $66.49 |
| P/E Ratio | $54.14 | ★ N/A |
| Revenue Growth | N/A | ★ 14.85 |
| 52 Week Low | $12.77 | $0.78 |
| 52 Week High | $16.59 | $4.98 |
| Indicator | RMBI | ADCT |
|---|---|---|
| Relative Strength Index (RSI) | 51.72 | 31.24 |
| Support Level | $13.10 | $0.78 |
| Resistance Level | $16.04 | $4.68 |
| Average True Range (ATR) | 0.56 | 0.10 |
| MACD | 0.06 | 0.10 |
| Stochastic Oscillator | 33.49 | 87.95 |
Richmond Mutual Bancorp Inc is a bank holding company. Along with its subsidiary, it is mainly engaged in attracting deposits from the general public, as well as brokered deposits, and investing those funds in loans secured by commercial and multi-family real estate, first mortgages on owner-occupied, one- to four-family residences, a variety of consumer loans, direct financing leases, and commercial and industrial loans. It also obtains funds by utilizing Federal Home Loan Bank (FHLB) advances. These funds are generally invested in investment securities, including mortgage-backed and mortgage-related securities and agency and municipal bonds. The Group's primary market area includes Wayne and Shelby counties in Indiana and Shelby, Miami, and Franklin counties in Ohio.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).